| Budget Amount *help |
¥18,070,000 (Direct Cost: ¥13,900,000、Indirect Cost: ¥4,170,000)
Fiscal Year 2011: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2010: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2009: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2008: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
|
|---|
| Research Abstract |
[18F]FRP170,1-(2-fluoro-1-[hydroxymethyl]ethoxy)methyl-2-nitroimidazole, is a new PET tracer for imaging hypoxia which was developed by the principal researcher and his colleagues of this Grant-in-Aid for Scientific research. The usefulness of [18F]FRP-170 for a treatment for a tailor-made treatment of cancer was investigated by looking at the relationship between the rate of FRP-170 uptake of tumor and the radiation responsiveness, the hypoxia related gene expression in the resected lung cancer, benign or malignant glioma, and O2 partial pressure in the malignant glioma. The results obtained from these clinical investigation were all positive for the usefulness of the drug. [18F]FRP-170, therefore, is strongly suggested to be a promising new hypoxia marker to establish a tailor-made-treatment of cancer.
|
